Clinical Scorecard: The Challenges of Bringing Retinal Therapies to Market
At a Glance
| Category | Detail |
|---|---|
| Condition | Development and delivery of emerging retinal therapies |
| Key Mechanisms | Pharmaceutical, gene and cell therapies, retinal implants, and AI-enabled imaging technologies |
| Target Population | Patients with retinal diseases, including rare retinal diseases and severe retinal degeneration |
| Care Setting | Retinal clinical research and care, including clinical trials, surgical treatment, rehabilitation, and reimbursement planning |
Key Highlights
- Clinical efficacy is only one factor affecting whether a retinal therapy reaches clinical practice; regulatory, manufacturing, reimbursement, and treatment-delivery challenges also matter.
- AI-based imaging analysis may support patient identification, endpoint development, and clinical trial design, while regulatory considerations depend on how the technology is used.
- For therapies intended to restore vision in severe retinal degeneration, panelists emphasized assessing functional improvements meaningful to patients, not relying only on conventional visual acuity endpoints.
- Rare-disease development can be complicated by patient recruitment and limited natural history data; panelists described partnerships with investigators and academic institutions as important resources.
- Cell and gene therapy development requires attention to manufacturing capacity, storage, preparation, surgical training, patient awareness, and post-treatment support.
Guideline-Based Recommendations
Diagnosis
- The panel discussion identified AI-based imaging analysis as a potential tool for identifying eligible trial participants and characterizing disease.
- Panelists called for greater standardization of ophthalmic imaging data, including broader adoption of DICOM standards.
Management
- Engage regulators early, particularly when new technologies challenge established approaches to evaluating efficacy.
- Select endpoints that reflect the therapy’s mechanism of action and functional outcomes meaningful to patients.
- Plan manufacturing capacity, product storage and preparation, surgical training, and patient support alongside clinical development.
- Begin reimbursement planning before regulatory approval and assess potential effects on health care costs and clinical outcomes.
Monitoring & Follow-up
- Consider whether trial design addresses statistical power, endpoint selection, patient recruitment, and disease heterogeneity.
- For cell and gene therapies, address manufacturing process variability and capacity as development progresses.
- For retinal implants, consider rehabilitation and support after implantation as part of the patient journey.
Risks
- Regulatory uncertainty may affect the use of AI-derived measurements, particularly when they serve as efficacy endpoints.
- Limited patient recruitment and natural history data can complicate trials for rare retinal diseases.
- Manufacturing capacity may lag behind accelerated clinical development and require substantial investment before approval.
- Without reimbursement, patients may be unable to access a therapy.
Patient & Prescribing Data
Patients with retinal diseases, including rare diseases, geographic atrophy, and severe retinal degeneration; the article does not provide prescribing criteria.
The article discusses development and commercialization considerations rather than prescribing regimens. It notes that retinal implant care may include surgery and rehabilitation, and that cell and gene therapies require planning for storage, preparation, and surgical training.
Clinical Best Practices
- Design endpoints to capture functional changes relevant to patients and appropriate to the therapy’s mechanism.
- Use experienced clinical investigators and external partners when internal expertise or resources are limited.
- Standardize ophthalmic imaging data to support research and clinical trial use.
- Plan for the full treatment pathway, including manufacturing, reimbursement, delivery, and post-procedure rehabilitation.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.







